Daiichi Sankyo: Not Exciting Enough For This Market, Apparently (OTCMKTS:DSKYF)
· seekingalpha.com
Daiichi Sankyo is a Buy, citing ADC pipeline growth led by trastuzumab deruxtecan, new approvals, and 2H 2026 catalysts. Click for this DSKYF stock update.
I am now a contributor to Total Pharma Tracker, where you can join me for discussions, get my follow-ups on ideas, and specifically request ideas to explore. It...